Key facts
- It has raised $9.9M; the latest was Seed Round ($9.6M) in Dec 2024.
- Notable investors include High-Tech Gründerfonds, STARTPLATZ, NRW.Bank, Boehringer Ingelheim Venture Fund, Infinitas Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Refoxy Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Refoxy Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Refoxy Pharma
Developer of therapeutic medicines designed to treat age-related diseases and improve healthy longevity. The company researches proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.
- Sector
- Healthcare
- HQ
- Cologne, Germany
- Founded
- 2020
- Employees
- 4
- Website
- refoxy.com/
- Ownership
- Privately Held (backing)
Refoxy Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Refoxy Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Refoxy Pharma in its N-PORT filings yet. We sweep new filings monthly.